Sona Nanotech shares fell 68 percent on Friday after the Halifax life sciences company announced it had ended the clinical trials of its saliva-based rapid test for COVID-19 due to disappointing results.
The company had been conducting trials at Humber River Hospital in Toronto to determine the efficacy of its rapid antigen saliva test for COVID-19. Early Friday, Sona said preliminary results had produced “inadequate test sensitivity” and it was discontinuing the trials.
In an interview Sunday, CEO David Regan said the company will now take stock, examine data from the trials, and then move